GlassScriptPhysician profile
Josef J Vesely
NPI 1427043900
$5,509.13
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,233 · 2020: $1,402 · 2021: $2,217 · 2022: $308 · 2023: $311 · 2024: $38.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $349.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $1,007.81 | 2019-2022 | |
| Novo Nordisk INC | $706.49 | 2019-2023 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $622.65 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $381.20 | 2019-2021 | |
| Abbott Laboratories | $352.88 | 2019-2023 | Aveir |
| Sanofi US Services INC. | $350.00 | 2021 | |
| Lilly USA, LLC | $318.59 | 2019-2021 | |
| Becton, Dickinson and Company | $300.00 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $300.00 | 2019 | |
| Corcept Therapeutics | $280.56 | 2020-2024 | Korlym |
| Genzyme Corporation | $182.00 | 2019-2020 | |
| Horizon Therapeutics Plc | $147.66 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.08 | 2020-2022 | |
| Amgen INC. | $108.34 | 2020 | |
| Dexcom, INC. | $56.07 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $53.66 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.15 | 2020-2021 | |
| Ascendis Pharma Endocrinology INC | $25.48 | 2023 | |
| Kyowa Kirin, INC. | $23.38 | 2023 | |
| Recordati_rare_diseases_inc. | $23.35 | 2021 | |
| Abbvie INC. | $23.05 | 2021 | |
| Tandem Diabetes Care, INC. | $22.15 | 2022 | |
| Insulet Corporation | $20.79 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $18.18 | 2021 | |
| Ibsa Pharma INC. | $17.15 | 2021 | |
| Shire North American Group INC | $15.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josef Vesely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.